On August 24, WUXI BIO fell 3.33% in regular trading, trading at HK$49.06/share, with turnover of HK$289 million. The stock had reached a 52-week high on August 20, accumulating significant gains in recent sessions.

On the news front, the CXO sector broadly retreated, with peers GenScript Biotech down 3.43%, WuXi XDC down 3.63%, and WuXi AppTec down 2.04%, reflecting sector-wide selling pressure. Ahead of the company's board meeting scheduled for August 25 to review interim results, some investors appear to be locking in profits before the earnings release.

The sector had previously rallied on multiple catalysts including Moderna's mRNA cancer vaccine Phase III clinical trial reaching its primary endpoint, driving sustained gains across CXO names. The current pullback reflects short-term profit-taking pressure being released after the extended run-up. The upcoming interim results review adds an additional layer of uncertainty prompting position adjustments.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)